Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, the company then branched out into the study of both cytokine and tyrosine kinase receptors. Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker.
About Regeneron Pharmaceuticals in brief
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York, about 25 miles north of Midtown Manhattan. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, the company then branched out into the study of both cytokine and tyrosine kinase receptors. Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. On March 26, 2012, Bloomberg announced that Sanofi and Regeneron were in development of a new drug which would help reduce cholesterol up to 72% more than its competitors.
In July 2020, under Operation Warp Speed, Regeneron was awarded a USD 450 million government contract to manufacture and supply its experimental treatment REGN-COV2. In October 2020 when U.S. President Donald Trump was infected with COVID-19 and taken to Walter Reed Medical Center in Bethesda, Maryland, he was administered RE GN2. Regeneron expected to produce 70,000-300,000 treatment doses or 420,000–1,300,00 prevention doses. In 2019, Regeneran Pharmaceuticals was announced the 7th best stock of the 2010s, with a total return of 1,457%. Regeneran was home to the two highest-paid pharmaceutical executives as of 2020.
You want to know more about Regeneron Pharmaceuticals?
This page is based on the article Regeneron Pharmaceuticals published in Wikipedia (as of Dec. 14, 2020) and was automatically summarized using artificial intelligence.
